Aligos Therapeutics, Inc.
$6.51
▲
2.97%
2026-04-21 05:13:00
www.aligos.com
NCM: ALGS
Explore Aligos Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$41.33 M
Current Price
$6.51
52W High / Low
$13.69 / $4.2
Stock P/E
—
Book Value
$8.67
Dividend Yield
—
ROCE
-130.74%
ROE
-1.97%
Face Value
—
EPS
$-2.45
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
82
Beta
2.62
Debt / Equity
9.8
Current Ratio
3.9
Quick Ratio
3.9
Forward P/E
-1.5
Price / Sales
22.63
Enterprise Value
$-23.12 M
EV / EBITDA
0.27
EV / Revenue
-10.58
Rating
None
Target Price
$65.8
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Protagonist Therapeutics, Inc. | $104.42 | — | $6.74 B | — | -25.39% | -20.18% | $107.84 / $41.28 | $9.82 |
| 2. | Regeneron Pharmaceuticals, Inc. | $753.59 | 17.99 | $79.36 B | 0.5% | 10.23% | 14.86% | $821.11 / $476.49 | $304.65 |
| 3. | Atossa Therapeutics, Inc. | $6.17 | — | $50.2 M | — | -94.38% | -62.74% | $19.35 / $3.76 | $4.57 |
| 4. | Pyxis Oncology, Inc. | $1.7 | — | $104.3 M | — | -119.93% | -91.44% | $5.55 / $0.89 | $0.85 |
| 5. | Phathom Pharmaceuticals, Inc. | $13.47 | — | $1.04 B | — | -125.87% | 63.97% | $18.31 / $2.21 | $-6.13 |
| 6. | Reviva Pharmaceuticals Holdings, Inc. | $0.91 | — | $10.89 M | — | -233.59% | -4.2% | $23.2 / $0.59 | $1.47 |
| 7. | LeonaBio, Inc. | $9.38 | — | $83.23 M | — | -76.55% | -2.91% | $14.21 / $2.2 | $5.2 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.17 M | 0.74 M | 0.96 M | 0.31 M | 0.63 M | — |
| Operating Profit | -21.81 M | -28.36 M | -18.57 M | -19.24 M | -20.56 M | — |
| Net Profit | -19.88 M | -31.54 M | -15.86 M | 43.09 M | -82.15 M | — |
| EPS in Rs | -3.69 | -5.85 | -2.94 | 8 | -15.25 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.19 M | 3.94 M | 15.53 M | 13.91 M |
| Operating Profit | -87.98 M | -89.15 M | -88.13 M | -97.58 M |
| Net Profit | -24.19 M | -131.21 M | -87.68 M | -96.05 M |
| EPS in Rs | -4.49 | -24.35 | -16.27 | -17.83 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 88.53 M | 70.09 M | 151.53 M | 146.69 M |
| Total Liabilities | 34.99 M | 99.07 M | 59.45 M | 42.79 M |
| Equity | 53.55 M | -28.97 M | 92.08 M | 103.9 M |
| Current Assets | 82.86 M | 62.14 M | 141.08 M | 133.54 M |
| Current Liabilities | 21.23 M | 21.74 M | 23.91 M | 33.13 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -82.5 M | -80.74 M | -79 M | -79.39 M |
| Investing CF | -37.83 M | -18.28 M | 44.98 M | -26.29 M |
| Financing CF | 101.64 M | 0.35 M | 88.33 M | 0.16 M |
| Free CF | -82.94 M | -80.87 M | -79.02 M | -80.33 M |
| Capex | -0.44 M | -0.13 M | -0.02 M | -0.94 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -74.6% | 11.66% | — | — |
| Earnings Growth % | -49.65% | 8.71% | — | — |
| Profit Margin % | -3326.01% | -564.61% | -690.63% | — |
| Operating Margin % | -2259.92% | -567.5% | -701.66% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -2193.46% | -547.74% | -675.24% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-08-19 | 1:0.04 |